INDEX ADVERTISING low tar cigarettea, 371372 AGE FACTORS arterial disease prevalence, 133-134 atheroecleroais and smoking rela- tionship, 32 atherosclerosis, aortic aneurysm, and smoking relationship, 194 cardiovascular disease mortality trends, 331 cerebrovascular d&ease risk, 5, 8 cessation attempts, 1611, 370, 373 CHD mortality, 7, 113, 128, 339, 352, 354 CHD relationship, 75-76, 91, 92, 101-102, 133-134 daily cigarette consumption, 10, 367, 373 intermittent claudication preva- lence, 184 prevalence of smoking, 10, 259, 365.366, 373 stroke incidence, 165-166, 171 stroke mortality trends, 341 ALCOHOL CONSUMPTION CHD mortality relationship, lll- 112 CHD relationship, 68, 91 coronary calcification relationship, 32 lipoprotein level relationship, 96 stroke risk factor, 162 sudden cardiac death relationship, 104-105 ALLERGY tobacco allergy and cardiovascular effects, 55-56, 133-189 AMISH mortality, 126127 AMPUTATION healing failure and smoking, 192 ANGINA PECTGRIS carbon monoxide exposure and ex- ercise tolerance, 136, 223 ANGINA PECI'ORIS-Contd. carboxyhemoglobin level, 223 CHD manifestation, 67, 7&71 incidence in Belfast, 34 incidence in smokem with CHD, 213 risk in female smokers, 102 smoking relationship, 70, 77, 36-37 AORTA aneurysm diagnosis, 192 aneurysm prevalence in smokers and nonsmokers, 45 atherosclerosis and nicotine expo sure, 50 atherosclerosis and smoking, 22, 34, -,56 atherceclerosie as cause, 16 atherosclerosis development, 5, 18 epidemiologic data, 194-195 mortahty trends, 341 tobacco smoke effects in rata, 53 ARTERIOSCLEROSIS See also ATHEROSCLEROSIS) angina pectoris relationship, 70 carbon disulfide exposure relation- ship, 226 cardiovascular disease causation, 5 definition, 15 mortality trends, 341 percent attributable to smoking, 65 underlying process of stroke, 340 ATHEROMA definition, 15 small arteries of myocardium, 34 ATHEROSCLEROSIS L%? also ARTEIuosCLERosIs) age and smoking relationship, 194 aortic aneurysm relationship, 192 atherogenesis, 19-21 cadmium exposure relationship, 227 carbon monoxide expoeure relation- ship, 223 cardiac arrest, 69 cardiovascular disease causation, 5 INDEX ATHEROSCLEROSIS-Contd. clinical significance, 16-17 definition, 15-16 dietary cholesterol effect, 196 epidemiologic studies, 21-48 incidence in smokers and nonsmok- ers, 67 literature reviews, 17 mortality and smoking, 229 natural history, 17-19 nicotine effects, 216 pathophysiologic mechanisms of to bacca smoke, 48, 56-5~ plasma triglyceride correlation, 181 risk factors, 205-206 severity trends, 343344 smoking cessation effects, 5 smoking effecta, 5-6 topographic distribution, 18 BLOOD FLOW nicotine and tobacco smoke effects, 189 nicotine effects, 215 smoking relationship, 187-188 BLOOD PRESSURE c3ee cd90 HYPERTENSION) CHD risk factor, 97-98, 108, 130, 134 coronary atherosclerosis relation- ship, 33 intermittent claudication relation- ship, 184 intervention trial effects, 315, 317 intervention trial for single risk factor, 300 nicotine effects, 3, 215 race factors, 77 smoking cessation relationship, 96- 97 smoking relationship, 55, 96-97, 187-188 BODY FAT CHD risk factors, 132 BODY WEIGHT Bee also OBESITY) smokers versus nonsmokers, 55 smoking effect in baboons, 196 stroke incidence relationship, 163 sudden cardiac death risk factor, 104 CADMIUM physiological effects, 226-227 tobacco smoke constituent, 226 Cancer See NEOPLASMS CARBON DISULFIDE arteriosclerotic diseases, as risk fat- tar, 226 CARBON MONOXIDE atherogenic effects, 5, 51-52 blood levels in smoking baboons, 196 cardiovascular disease relationship, 220, 222-224 cardiovascular effects, 230 chemistry, 219-226 exercise tolerance relationship, 186 fibrinolysis relationship, 187 myocardmi infarction risk, 229 platelet adhesiveness relationship, 189-190 steelworkers' exposure and CHD mortality, 111 toxicologic effects, 9 validation of self-reported smoking cessation, 245, 261 CARBONYL SULFIDE atherosclerotic effecta, 225 Catecholaminea See EPINEPH- RINIQ NOREPINEPHRINE CENTRAL NERVOUS SYSTEM nicotine effects, 213 CEREBROVASCULAR DISEASE s?e also STROKE) atherosclerosis of cerebral vascuia- ture, 48 cerebral thrombosis incidence, 344 cessation of smoking relationship, 168 incidence trends, 344 morbidity and mortality, 159469 mortality trends, 329, 346 oral contraceptives relationship, 168-171 prevention, 170 risk factors, l-162, X8-171 smoking as risk factor, 5, 8, 162- 166 subarachnoid hemorrhage, 5, 8, 167 transient ischemic attacks, 166-167 CESSATION OF SMOKING hsee aLso Ex-sMoK.EI& REDUG TION OF SMOKING; SMOK- ING INTERVENTION TRI- ALS) attempts to quit, 16-11, 369370, 373 blood pressure correlation, 96-97 INDEX CESSATION OF SMOKING-ConM. CHD epidemiology, 243-233, 3CG 321 CHD mortality rates, 8-10, 122 126, 123, 29-21 definition in intervention trials, 246-247 following cardiovascular events, 213, 215 intervention trial effecta, 9, 252, 257-258, 261, 264-271, 275, 27% 279,28%283 peripheral vascular disease treat- ment, 5, 8, 179, 190, 192, 194 peripheral vascular effects, 187-188 stroke mortality risk, 168 stroke prevention, 176 sudden cardiac death risk, 7, 105 validation of self-reports, 244-246, 258, 261, 265, 27C280, 305, 312 CHEROOT SMOKERS myocardial infarction risk, 88 CHEWING TOBACCO intermittent claudication relation- Ship, 186 CH0LIBTRR0L (See a&o DIETi LIPIDS; LIPO- PROTRINS) aortic tissue levels following smoke exposure, 219 atherogenesis relationship, l%ZO, 50-54, 216-217 atherosclerosis and diet in rabbita, 189-191 carbon monoxide, diet, and athero- sclercais, 223 cardiovascular disease risk and blood levels, 265 CHD risk, 5, 7, 89, 91-93, 96-100, 127, 129130, 136. 344 coronary atherosclerosis and serum levels, 53 hypercholesterolemia prevalence, 346 intermittent claudication and se rum levels, 184 intervention trial effects, 312-313, 315, 317 intervention trials for single risk factor, 309 myocardial infarction and serum levels, 165 peripheral vascular disease rela- tionship, 180-182, 184 CHOLESTRR0L-Cont.d. smoking and blood levels, 188, 224 smoking and serum levels, 6, 56, 182 stroke risk predictor, 161 sudden cardiac death and serum levels, 104 CHRONIC OBSTRUCTIVE PUL MONARY DISEASE (See .aIso EMPHYSEMA) mortality trends, 333, 338-340 smoking correlation, 228 CIGAR SMOKERS aortic lesions, 194 CI-ID mortality, 8, 122 CHD risk, 86, 123 coronary event risk, 76-77 former cig-arette smokers, 252 inhalation avoidance, 212 myocardA infarction risk, 88 peripheral vascular disease risk, 191 stroke mortality, 163 thiocyanate elevation, 244 COFFEE CONSUMPTION blood lipid effecta, 182 CHD risk factor, 91, 97 stroke risk factor, 162 CORONARY ARTERIES atherosclerosis in, 18 atherosclerotic lesions after nico- tine exposure, 50 carbon monoxide effect on lipid metabolism in, 52 smoking and atherosclerosis in, 22- 34, 56 CORONARY HEART DISEASE (See also MYOCARDIAL IN- FARCTION) age factors in smoking effect, 112 113, 116117, 123 atherosclerosis aa underlying cause, 16 cessation of smoking and epidemiol- ogy, 5-6, 10, 122-126, 128, 293 321 clinical manifestations, 67-71 death certificate ascertainment, 69- 70 incidence studies, 342343 intervention trial effects on inci- dence, 9 low risk populations, 126127 low yield cigarettes, 12%122, 128 INDEX CORONARY HEART DISRASE-Contd. DIET-Contd. mortality trends, 329, 334, 336, 336-346,34%362 pipe and cigar smokers, 122, 128 prevalence trenh, 3 prospective cohort studies, 106-113 risk assessment, 129-136 risk factor reduction and mortality trends, 344, 346-346 risk factors, 91-93, 96-97 smoking relationship, 4-3, 65-67, 113-119. 127-126 synergism among risk factors, 97- 100 treatment improvementa, 346 cigar smokers serum, 212 nicotine metabolite, 212-213 serum levels and uptake of particu- lates, 223 urine concentration in smoking ba- bOOM, 190 validation of self-reported cessation, 245 CROSS-CULTURAL STUDIES atherosclerosie topographic d&tribu- tion, 18 CHD incidence and mortality, 79- 91 Demographic Factor8 See-AGE FACTORS; EDUCATIONAL AT- TAINMRNT; RACE FACTORS; SEX FACTORS; SOCIOECO- NOMIC STATUS DIARRTESMRLLITUS atherogenesis relationship, 26 cardiovascular disease risk factor, 205 CHD incidence relationship, 89 CHD risk factor, 91-92 mortality trends, 334 peripheral vascular disease rela- tionship, 179, 183, 165, 191 prevalence, 346 stroke risk factor, 162, 165 DIRT (See also CHOLESTEROL; SATU- RATED FATS) atherogenesis correlation, 19-20 CHD mortality relationship, 112 high cholesterol diet, nicotine, and arterial damage, 50 nutritional etatus and smoking role in atherosclerosis, 33 treatment of peripheral vascular disease, 179 Dose-ReapoMe RelfttioMhip see SMOKING PATTERNS DRUG INTRRACTIONS atenolol physiologic effects in smokers, 136 diasepam reactivity in smokers, 222 methacholine effects on norepineph- rine, 216 norepinephrine effects of dimethyl- phenylpiperaxinium, 216 oxytremorine effecta on norepineph- rine, 216 phenacetin reactivity in smokers, 222 propranolol physiologic effecta in smokers, 166 EDUCATIONAL ATTAINMENT cessation attempt frequency rela- tionship, 369 cigarette con8umption relationship, 367 ELRCTROCARDIOGRAM abnormalities as stroke risk factor, 162-163, 166 CHD risk prediction, 134 intervention effect, 232 nitrogen dioxide exposure and car- diac function, 226 EMPHYSEMA Wee ah CHRONIC ORSTRUCTIVE PULMONARY DISRASR) cadmium exposure as risk factor, 226 nitrogen oxides exposure a8 rbrk factor, 226 smoking relationship, 223 ENZYMES carbon monoxide affinity, 222-223 RPINEPHRINE nicotine effects, 213, 215-216 plasma level8 and smoking, 166 ERYTHROCYTES (See ah HEMATOCRIT) counts in smokers, 55 nicotine effects in rabbits, 196 INDEX M-SMOKERS (See a&o CESSATION OF SMOK- ING) aortic lesions, 47, 194 atheroeclerceie mortality, 229 CI-ID incidence, 82 CHD mortality, 5-6, 8 death risk after my& infarc- tion or angina, 105 differences from smokers, 297 peripheral arterial disease in wom- en, 185 stroke mortality, 163, 166 FAMILY wives' participation in intervention trials, 257,260 Fmus (See also MATERNAL SMOKING) maternal cadmium administration effects on fetal brain in rata, 227 maternal smoking effecta, 189 FIBRINOGEN smoking effectas, 55, 18`7 FIBRINoLYsIS nicotine effects, 218 smoking effects, 55, 187 FILTER CIGARETTE3 (See also LOW YIELD CIGAR ETTES) carbon monoxide yields, 220 cardiovascular d&ease incidence, 228 CHD mortality effects, 8 CHD l-i& 120 hydrogen cyanide removal, 224-225 nicotine delivery, 210 nitrogen oxide reduction, 225 GLUCOSE atherogenesis and blood levels, 218 intermittent claudication and blood levels, 184 intolerance and peripheral vascular disease, 182 smoking and blood levels in baboons, 55, 190 HEART RATE atherogenesia correlation, 218 nicotine effecta, 3, 21%216 smoking effecta, 187 HEIGHT CHD risk factor, 107 stroke risk factor, 163 HEMAm (See a&o ERYTHRoCYTJC3) nicotine effects in rabbits, 190 smoking effects, 55, 187 HEMOGLOBIN carbon monoxide binding, 222 nicotine effecte in rabbits, 190 smoking effects, 55, 186-187 HEREDITY cadmilim-induced hypertension, 227 CHD risk factor, 91-92, 108 coronary disease history and platel- et activation, 55 stroke risk factor, 166 HORMONES estrogen and myocardial infarction, 103 * nicotine effecta on antidiuretic hor- mone secretion, 213 HYDROGEN CYANIDE coronary arteries and aorta effects, 52 serum thiocyanate a8 metabolite, 244 tobacco smoke constituent, 22-4 HYPERTENSION (See also BLOOD PRESSURE) atherogenesis relationship, 20 cadmium level relationship, 226- 227 cardiovascular disease risk factor, 205 CHD risk factor, 5, 7, 89, 91-93, 127. 344 educational campaign effects, 348 mortality trends, 329, 341 peripheral vascular disease rela- tionship, 179, 181 prevalence trends, 346 renal artery steno&, hypertension, and smoking relationship, 185 stroke risk factor, 161-163, 16!S- 166, 170, 340 sudden cardiac death risk factor, 104 IMMUNE SYSTEM alterations in smokers, 55-56 hypersensitivity and tar exposure, 228 INFLUENZA mortality trends, 334 INDEX INVOLUNTARY SMOJiJNG atherosclerotic cardiovascular die- ease etiolcgy, 166 Cotinine in urine of nonsmokers, 212213 KIDNEYS cadmium localization, 226 nicotine metabolism, 212 renal artery stenosis, hy-pertension, and smoking interrelationship, 135 atherosclerosie and lead in drink- ing water, 227 LEGISLATION smoking restrictions in F'inland, 279-280, 316 LEuKocYTm elevation in smokers, 55-56 nicotine effects. 190 LINOLEN-IC ACID CHD incidence and consumption, 86 LIPIDS (See also CHOLESTEROL) atherogenesis relationship, 19-21, 52-54, 217-218 carbon monoxide and blood levels, 223-224 dietary cholesterol and serum level, 190 nicotine administration and serum level, 190 race factor8 and plasma levels, 77 smoking and serum levels, 219 smoking Berum level8 in baboons, 190 LIPOPROTEINS atherogenic role, 21 cadmium exposure relationship in pigeons, 227 CHD incidence, 92 hyperlipoproteinemia and athero genesis, 20 hyperlipoproteinemia and peripher- al vascular disease, 130-181 oral contraceptives and smoking ef- fects, 104 race factors, 77 smoking effects, 6, 53, 54, 56, 93, 96, 136, 219 stroke relationship, 161-163 cadmium accumulation, 226 cirrhosis mortality trends, 334 lipoprotein metabolism impairment and peripheral vascular disease, 182 nicotine metabolism, 212 prOtein SyntheSi8 and carbon mon- oxide exposure, 222 LOW YIELD CIGAIWITES Hea also FILTER CIGAIEITES) cardiova8cular disease relation8hip, 229-230 CHD mortality effecta, 8, 120422, 123 smoking pattern effects, 9, 210, 218, 239, 272 stroke mortality relationship, 164- 165 LUNG CANCER Bee a&o NEOPLASMS) death8 in smoking intervention tri- ale, 30% 309 excess death8 attributable to emok- ins, 65 mortality trenda, 333, 338-339 LUNGS nicotine metabolism, 212 LYMPHOCYTES smoking effects in baboons, 199 LYSOSOMES nicotine effects, 219 MASS MEDIA in smoking intervention trials, 263- 264, 270, 272, 278-279, 231-233, 316 MATERNAL SMOKING See also FETUS) fetal cardiovascular effects, 189 umbilical artery changes, 219 MENOPAUSE CHD risk, 7, 101-104, 127 MORMONS CHD mortality, 126 MORTALITY calculations, 333, 356 cardiovascular disease mortality trend8, 329-344 cardiovascular disease risk factor reduction effects, 344-343 cessation of smoking effecta, S9, 194, 293-321 INDEX MORTALITY-Co&d. CHD mortality and smoking rela- tionship, 4, 7, 65-66, 113-128, 346-353 CHD mortality trends, 339-341 coronary care improvement effects, 343 prospective studies of CHD mortali. ty, 105-113 MYOCARDIAL INFARCTION (See also CORONARY HEART DISEASE) carbon monoxide exposure correla- tion, 51 carboxyhemoglobin level relation- ship, 223 cardiac arrest etiology, 69 casefatality trends, 344 CHD manifestation, 67 clinical manifestations, 6746 discharge rate trends, 344 free fatty acid elevation in smokers following myocardial infarction, 219 hyperlipoproteinemia in survivor8, 181 incidence, 342343 mortality trends, 33944.0 nicotine and carbon monoxide de- livery relationship, 229 oral contraceptive use a8 risk fac- tor, 7, 128 smoking a8 risk factor, 72-75, 77- 79, 64439, 91, 101-102, 105, 108, 121, 165 zinc deticiency correlation, 227 MYOCARDIUM atherosclero8i8 of small arteries, 34 MYOGLOBIN carbon monoxide binding, 222 NM)PLASMS See also LUNG CANCER) cancer death8 in smoking interven- tion trial, 306, 310 cancer mortality in Seventh Day Adventista, 126 cerebral neoplasm8 and stroke, 166 death rate8 and smoking patterns, 81 respiratory tract cancer mortality and smoking, 81 NICOTINE atherosclerosis pathogenesis, 5, 46, 50-51 blood flow effects, 189 blood pressure and heart rate ef- fects, 3 cardiovascular effects, 213, 215-219, 230 chemistry, 209-212 fibrinolysis relationship, 187 hematologic effects, 190 metabolism, 212-213 myocardial infarction risk, 229 particulate uptake and serum lev- els, 228 peripheral vascular effects, 187-138 serum lipid effects, 190 toxicologic effects, 9 validation of self-reported smoking cessation, 245 yield8 in U.S. cigarettes, 210 NICOTINE CHEWING GUM smoking intervention, 270 NITROGEN OXIDES coronary artery and aorta effecta of nitric oxide, 52 nitric oxide, carbon monoxide, and atherosclerotic change8, 225 tobacco smoke constituents, 22.5- 226 NOREPINEPHRINE nicotine effects, 213, 215-216 smoking and plasma levels, 136 OBESITY (See also BODY WEIGHT) atherosclerosis and smoking in- terrelationships, 31, 46 cardiovaecular disease risk factor, 205 CHD risk factor, 91, 92 lipoprotein level relationship, 96 stroke risk factor, 162 OCCUPATIONS farm laborers, 133-134 grade of employment and CHD mortality, 110-111 industrial workers, 275-278, 230- 282, 303, 314-315 nur8e8, 102 physiciams, 65, 110, 112, 123-124, 164,297 steelworkers, 111 381 INDEX ORAL coNTRAcEpTTvE8 CHD risk factor with smoking, 101-104, 126 myocardial infarction and smoking interrelationehips, 7 stroke risk factor with smoking, 166-171 subarachnoid hemorrhage and smoking interrelationships, 5, 8 PERIPHERAL VASCULAR DIS EASE anirnd StUdieS, 189-190 atheroeclerosis a8 underlying cawe, 16 cea8ation of smoking effecta, 190- 192, 194 clinical investigations, 166-189 diagnosis, 179 epidemiologic studies, 182-186 reactivity of patients to tobacco glycoprotein, 56 risk factors, 16&182, 194 smoking effecta, 8 treatment, 179-W PERSONALITY cardiovascular d&ease risk factor, 205 CI-ID risk factor, 91-93 PHYSICAL ACTIVITY cardiovascular disease risk, 205 CHD risk, 91-92, 132 exercise tolerance and carbon mon- oxide exposure. 166 stroke incidence, 162 treatment of peripheral vascular disease, 179 PIPE SMOKERS aortic lesions, 47. 194 CHD mortality effects, 8, 122, CHD risk, 66, 123 coronary event risk, 76-77 former cigarette smokers, 252 myccardial infarction risk, 66 peripheral vascular dieease risk, 191 stroke mortality, 163 thiocyanate elevation, 244 PLATELETS adhesiveness and carbon monoxide effects, 189-190 atherogenesis role, 217-219 nicotine effect in rabbits, 190 smoking effects, 6, 5556, 187 PLATELEB-&ntd. smoking effecta in baboons, 190 thrombocytopenia a8 stroke risk factor, 166 PNEUMONIA mortality trends, 334 PROSTAGLANDINS nicotine effecta and athemgeneais, 216-219 RACE FACTORS aortic aneury&ms and atheroecler+ Si8, 1% atheroecleroeia in aorta, 46 atheroeclerceis in coronary arteries, 22, 31 atheroeclemsis severity trends, 343- 344 Cardiova8cular disease mortality trends, 331 cerebrovascular disease incidence, 170 CHD incidence, 77-79, 132-134 CHD mortality, 339 hyperteneive diaea8e mortality trends, 341 lipoprotein levele, 93 prevalence of smoking, 364-365 8moking patterns, 77 stroke mortality, 159, 165, 341 RECIDIVISM rate following intervention trials, 261-263, 265 REDUCTION OF SMOKING criteria for succes8ful intervention, 245-247 intervention trial effecta, 9, 256, 258, 262, 264, 275, 279-2.80, 309, 311313, 315 peripheral vascular disease pa- tients, 191 nicotine effects, 213 REORGANIZED CHURCH OF JESUS CHRIST OF LATTER DAY SAINTS mortality rates, 126 SATURATED FATS (See also DIET) consumption trends, 348 diet and atherogenesis, 19 lipoprotein composition relation- Ship. 53 INDEX SEVENTH DAY ADVENTISTS CHD and cancer mortality, 126 SEX FACTORS Bea also WOMEN) aortic aneurysm mortality, 194 brain infarction and mywardial in- farction, 159 cessation attempts, 11, 373 CHD mortality, 110-113. 339 CHD mortality and smoking ceasa- tion trenda, 348-352 CHD rates, 7 cigarette consumption trends, 10, 36fx367, 373 lipoprotein levels, 93 peripheral vascular d&ease preva- lence, 184-185 8moking pattem8,7 smoking prevalence, 7, 364, 373 stroke incidence, 165, 344 stroke mortality, 164 sudden cardiac death incidence, 68 SMOKING HABIT prevalence trende, 336,344, 346- 350, 364-366, 373 Sweden, 111 SMOKING INTERVENTION TRI- Au3 ceesation outcome, 9, 267-271, 281- 283 wmmunity-ba8ed trial& 271-282, 314-318 individual clinical investigations, 249471. 303-313, 318. 320 methodological problems, 244-249, 264-267,28W281,30&302 SMOKING PATTERNS cefmation rate effect8,261 CHD incidence, 81433,128 CHD mortality rat+ 113, 115-119, 127 wronary event tik, 75-76 daily consumption trends, 373 intervention trial effecta, 9 low yield cigarettes, 9 myocardial infarction incidence, 87- 88 peripheral vascular disease rela- tionship, 185 raw factorm, 77 reduction of smoking effects, 262 stroke mortality rates, 163-164, 171 sudden cardiac death rick, 7. 104 trenda, 352 CHD incidence, 92 SMOKING PATTRRNS - Contd. women, 101-102, 104 SNUFF intermittent claudication relation- Ship, 186 SOCIOECONOMIC STATUS CHD mortality rates, 111-112, 339, 350-352 CHD risk factor, 91 coronary atherosclerosis and smok- ing interrelationships, 33 STRESS CHD risk factor, 91 STROKE Gee also CEREBROVASCUIAR DI!3RASEI atheroeclero+ as underlying cause, 16 discharge rate trends, 344 incidence study, 344 mortality trends, 334, 340-341 SUDDEN CARDIAC DEATH clinical manifestations, 68-69 risk factors, 104-105 smoking as risk factor in women, 102 smoking pattern relationship, 7, 128 TARS, TOBACCO smoking behavior relationship, 371- 372 tobacco smoke constituent, 227-228 yields in U.S. cigarettea, 228 THIOCYANATE blood levels in smoking baboons, 190 serum levels and lipoproteins, 182 validation of self-reported smoking cessation, 24&246,258,261-265, 279-280,305,312 TOBACCO SMOKE athemecleroek pathogeneais, 48, constituents, 8-9 physical and chemical characteris tics, 206!m TRIGLYCERIDES atherosclerosis and plasma wncen- tration, 181 CHD development and plasma lev- els, 84 INDEX TRIGLYCERIDEg-Contd. elevation in peripheral vascular disease, 160 nicotine effects, 219 stroke risk factor, 161, 165 VITAMIND arterial lesion8 in monkey8 caused by dietary excess, 50-51 WEIGHT GAIN cessation of smoking correlation, 96-97, 301 WOMEN (See also MENOPAUSE; ORAL CONTRACEPTIVRS; SM FACTORS) brain infarction and LDL cholester- ol, 162 cardiOva8dar disease mortality trend8, 331 CHD incidence, mortality, and smoking interrelation8hip8, lOl- 104, 127-126 subarachnoid hemorrhage risk and smoking, 5, 167, 170 ZINC t.obacco smoke constituent, 227 3234 .-.-